SPC
ADAP

Sigma Planning Corp’s Adaptimmune Therapeutics ADAP Stock Holding History

Sigma Planning Corp’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,209
Closed -$43K – 1376
2021
Q2 		$43K Buy
+10,209
New +$49.6K ﹤0.01% 1401

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sigma Planning Corp's ADAP Position: Q3 2021 in Review

Sigma Planning Corp sold out of Adaptimmune Therapeutics (ADAP) in Q3 2021, closing a stake of 10,209 shares — an estimated $43K sold.

Sigma Planning Corp first reported a position in ADAP in Q2 2021 and held it in 1 quarter. The position peaked at $43K in Q2 2021. 92 funds tracked by Wall St. Rank hold ADAP as of Q3 2021.

  • Sigma Planning Corp reported no remaining Adaptimmune Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Sigma Planning Corp sold 10,209 Adaptimmune Therapeutics shares in Q3 2021, an estimated $43K.
  • Sigma Planning Corp first reported a position in Adaptimmune Therapeutics in Q2 2021 and held it in 1 quarter.
  • Sigma Planning Corp's Adaptimmune Therapeutics position peaked at $43K in Q2 2021.
  • 92 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2021.

Based on Sigma Planning Corp's 13F filing for Q3 2021, filed 28 Oct 2021.